Merck & Company, Inc. vs Revolution Medicines, Inc. — Stock Comparison
Q·Score Breakdown
6.7
Neutral
Overall
5.1
Bearish
Quality
Health
Growth
Valuation
Sentiment
MRK
Forward P/E of 11.5× is low relative to sector peers.
RVMD
100% of 21 covering analysts have a positive rating.
⚠ low return on equity (-58%).
Analyst Consensus
BUY
Target $129.74 (+15.7%)
27 analysts
BUY
Target $174.30 (+25.0%)
20 analysts
Fundamentals
MRK
RVMD
31.5×
Trailing P/E
—
11.5×
Forward P/E
-26.6×
13.6%
Profit Margin
0.0%
76.6%
Gross Margin
0.0%
—
ROE
-58.1%
4.9%
Revenue Growth
—
—
Earnings Growth
—
0.28
Beta
1.01
—
Price / Book
—
$277.0B
Market Cap
$29.7B
$73 – $125
52-Week Range
$34 – $156
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →